Johnson & Johnson: Quality in Uncertain Times
Johnson & Johnson (NYSE: JNJ) reported better-than-expected results for the second quarter of 2026, once again demonstrating the strength of its broadly diversified healthcare business. While reported earnings remained nearly unchanged due to special effects related to acquisitions and restructuring, operational development continued positively across all major business segments.
Furthermore, management raised the full-year 2026 guidance, underscoring confidence in continued robust demand for innovative medicines and medical technology – despite the ongoing challenging macroeconomic environment.
Q2 2026 at a Glance
| Key Figure | Q2 2026 | Year-over-Year Change |
|---|---|---|
| Revenue | $25.3 billion | +6,6 % |
| Operational Revenue Growth | – | +5,6 % |
| Adjusted EPS | $2.90 | +4,7 % |
| Adjusted Net Income | $7.1 billion | +5,7 % |
| Free Cash Flow | approx. $8.7 billion | approx. +40% |
Key Highlights
- Revenue exceeded market expectations, driven by broad-based growth in the Innovative Medicine and MedTech segments.
- The operational revenue growth of 5.6% reflects continued strong demand despite negative currency effects.
- Adjusted earnings per share (EPS) rose to $2.90, supported by improved operational efficiency and consistent execution of the corporate strategy.
- Free cash flow increased significantly, further strengthening the group’s already solid financial position.
- Management raised the 2026 full-year guidance, signaling confidence in further business development.
What Defined the Quarter?
The most important growth drivers once again came from the Innovative Medicine segment. In particular, the therapeutic areas of oncology, immunology, and neuroscience recorded sustained strong demand.
The MedTech segment also continued its positive trend. A further recovery in procedure volumes and the gradual normalization of procurement activities in hospitals provided additional growth momentum.
Segment Revenue – Q2 2026
| Segment | Q2 2026 (M USD) | Q2 2025 (M USD) | Reported Growth | Operational Growth |
|---|---|---|---|---|
| Innovative | 27x | approx. 21–24x | +7,8 % | +6,8 % |
| Medicine MedTech | 28 % | approx. 22–28% | +4,5 % | +3,6 % |
| Group Total | approx. 6% | approx. 4–7% | +6,6 % | +5,6 % |
Source: Johnson & Johnson, Q2 2026 Quarterly Report.
MUMAK Assessment
The current quarterly figures confirm our positive long-term assessment of Johnson & Johnson.
The combination of stable cash flows, improved earnings quality, a broadly diversified healthcare portfolio , and the raised full-year guidance underscores the company’s current role as a defensive core holding within the UMBRELLA strategy. UMBRELLA Strategy.
